Biotronik announces positive trial data for Passeo-18 balloon

Biotronik has announced positive 12-month data from Biolux P-I, a new study assessing the benefits of its Passeo-18 Lux Paclitaxel Releasing Balloon.

In the randomised controlled study, the stent was shown to provide excellent clinical outcomes among sufferers of de novo and restenotic femoropopliteal lesions.

After one year, 84.6 percent of patients treated with Passeo-18 Lux experienced freedom from target lesion revascularisation, compared to 58.3 percent of patients treated with an uncoated percutaneous transluminal angioplasty catheter.

Moreover, the Biotronik device was shown to be highly deliverable and easy to use compared with other treatment options.

Alain Aimonetti, vice-president of sales and business development at Biotronik's vascular intervention division, said: "Our significant investments in developing outstanding peripheral vascular devices are being translated into real clinical benefits for patients and physicians."

Earlier this month, the company was granted CE Mark approval for Iforia, its latest cardioverter-defibrillator/cardiac resynchronisation therapy defibrillator device.